The MUSC Hematology/Oncology Fellowship Program began in 1986 and currently accepts four trainees into each class for the three-year combined hematology/oncology training program, the only hematology/oncology training program in the state of South Carolina. This program provides each fellow extensive clinical training in outpatient, inpatient, and consultative medical oncology and benign and malignant hematology, including autologous and allogeneic stem cell transplantation. Training in the basic principles and practice of hematology/oncology clinical research is provided to all fellows; additional training in basic and/or clinical research is available. The program also offers an opportunity for select fellows to obtain a Master of Science in Clinical Research starting in parallel with the final year of fellowship training.
In general, the first two years of training are focused on standard clinical matters leading to completion of all board certification requirements. The remainder of the second year and all of the third year are flexible, individualized based upon the fellow's interest and as guided by their career pathway. The Scope of Practice includes details about the pathways and the expectations. Fellows also serve as educators for lower-level trainees and participate in institutional quality improvement activities, such as the American Society of Clinical Oncology's Quality Oncology Practice Initiative.
The program only accepts July 1 matriculates, and applications for matriculation in a given year are accepted only through the AAMC's ERAS system beginning July 1, twelve months prior to the intended date of matriculation; the program has participated in the NRMP's "Match" system for assignment of hematology/oncology fellowship positions since 2006 and presently plans to continue its participation. All applications for matriculation July 1 should be completed no later than August 15 in the year prior in order to be considered. Interview dates are typically in the fall. The program will consider applicants who have J1 Visas and can maintain J1-status throughout the three year fellowship. Unfortunately, we cannot sponsor H1B Visas. Applicants must be considered actively board-certified or board-eligible in internal medicine by the American Board of Internal Medicine or presently be in an internal medicine training program leading to such certification. Candidates who have passed the USMLE Step 3 exam are preferred, as passage of Step 3 is an institutional requirement for fellowship matriculation.
The Hematology/Oncology Fellowship is fully integrated with the clinical and translational research programs at MUSC's Hollings Cancer Center, affording them the opportunity for laboratory experinces, collaborative engagement, and participation in translational medicine. Fellows are expected to take advantage of the clinical and laboratory research activities and opportunities of the Cancer Center, including the grant mechanisms. The Hollings Cancer Center is a National Cancer Institute (NCI)-designated cancer center, the only such institution in the state.